Search

Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma | NEJM - nejm.org

1diawanita.blogspot.com

Abstract

Background

In a pilot study involving patients with cutaneous squamous-cell carcinoma, a high percentage of patients had a pathological complete response with the use of two doses of neoadjuvant cemiplimab before surgery. Data from a phase 2 study are needed to confirm these findings.

Methods

We conducted a phase 2, confirmatory, multicenter, nonrandomized study to evaluate cemiplimab as neoadjuvant therapy in patients with resectable stage II, III, or IV (M0) cutaneous squamous-cell carcinoma. Patients received cemiplimab, administered at a dose of 350 mg every 3 weeks for up to four doses, before undergoing surgery with curative intent. The primary end point was a pathological complete response (the absence of viable tumor cells in the surgical specimen) on independent review at a central laboratory, with a null hypothesis that a pathological complete response would be observed in 25% of patients. Key secondary end points included a pathological major response (the presence of viable tumor cells that constitute ≤10% of the surgical specimen) on independent review, a pathological complete response and a pathological major response on investigator assessment at a local laboratory, an objective response on imaging, and adverse events.

Results

A total of 79 patients were enrolled and received neoadjuvant cemiplimab. On independent review, a pathological complete response was observed in 40 patients (51%; 95% confidence interval [CI], 39 to 62) and a pathological major response in 10 patients (13%; 95% CI, 6 to 22). These results were consistent with the pathological responses determined on investigator assessment. An objective response on imaging was observed in 54 patients (68%; 95% CI, 57 to 78). Adverse events of any grade that occurred during the study period, regardless of whether they were attributed to the study treatment, were observed in 69 patients (87%). Grade 3 or higher adverse events that occurred during the study period were observed in 14 patients (18%).

Conclusions

Neoadjuvant therapy with cemiplimab was associated with a pathological complete response in a high percentage of patients with resectable cutaneous squamous-cell carcinoma. (Funded by Regeneron Pharmaceuticals and Sanofi; ClinicalTrials.gov number, NCT04154943.)

Adblock test (Why?)



"stage" - Google News
September 12, 2022 at 03:16PM
https://ift.tt/YXWCvFL

Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma | NEJM - nejm.org
"stage" - Google News
https://ift.tt/IGnKMpJ
https://ift.tt/jXtYSeV

Bagikan Berita Ini

0 Response to "Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma | NEJM - nejm.org"

Post a Comment

Powered by Blogger.